Ground Swell Capital LLC Purchases New Holdings in Haleon plc (NYSE:HLN)

Ground Swell Capital LLC purchased a new stake in Haleon plc (NYSE:HLN) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 15,813 shares of the company’s stock, valued at approximately $151,000.

Several other institutional investors have also recently made changes to their positions in the stock. Addison Advisors LLC increased its holdings in Haleon by 28.7% during the fourth quarter. Addison Advisors LLC now owns 4,954 shares of the company’s stock worth $47,000 after buying an additional 1,106 shares during the last quarter. Haverford Trust Co lifted its stake in Haleon by 5.0% in the fourth quarter. Haverford Trust Co now owns 25,842 shares of the company’s stock valued at $247,000 after acquiring an additional 1,233 shares during the last quarter. Bessemer Group Inc. grew its position in shares of Haleon by 5.9% in the 4th quarter. Bessemer Group Inc. now owns 22,301 shares of the company’s stock valued at $212,000 after acquiring an additional 1,236 shares during the period. United Capital Financial Advisors LLC raised its holdings in shares of Haleon by 3.5% in the 4th quarter. United Capital Financial Advisors LLC now owns 37,475 shares of the company’s stock valued at $358,000 after purchasing an additional 1,266 shares during the period. Finally, FIL Ltd raised its holdings in shares of Haleon by 45.7% in the 4th quarter. FIL Ltd now owns 4,049 shares of the company’s stock valued at $39,000 after purchasing an additional 1,270 shares during the period. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Stock Up 1.7 %

HLN stock opened at $10.75 on Friday. The business’s fifty day moving average price is $10.20 and its two-hundred day moving average price is $9.84. The stock has a market capitalization of $48.50 billion, a price-to-earnings ratio of 31.62, a PEG ratio of 2.82 and a beta of 0.24. Haleon plc has a fifty-two week low of $8.22 and a fifty-two week high of $10.85. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58.

Haleon (NYSE:HLN) last released its quarterly earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. The business had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. On average, equities analysts anticipate that Haleon plc will post 0.43 earnings per share for the current year.

Haleon Increases Dividend

The business also recently declared a — dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be paid a $0.1166 dividend. This is a boost from Haleon’s previous — dividend of $0.05. This represents a dividend yield of 1.6%. The ex-dividend date of this dividend is Friday, April 25th. Haleon’s payout ratio is 58.97%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on HLN. Barclays reissued an “overweight” rating on shares of Haleon in a research report on Tuesday. HSBC reissued a “hold” rating on shares of Haleon in a report on Wednesday, March 5th. Hsbc Global Res cut shares of Haleon from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Morgan Stanley raised shares of Haleon from an “equal weight” rating to an “overweight” rating and set a $11.25 price objective on the stock in a research report on Friday. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Haleon in a report on Monday, March 3rd. Five research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $11.25.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.